Skip to main content
. 2022 Mar 17;13:851497. doi: 10.3389/fimmu.2022.851497

Figure 4.

Figure 4

Plasma total DNA concentrations and myeloperoxidase–DNA levels are higher in COVID-19 patients who will subsequently have pulmonary embolism but not when assessed by comparable severity. Plasma NET levels were compared between COVID-19 patients who will subsequently develop pulmonary embolism (PE) (n = 19) and those who will not (n = 77). (A) Total DNA concentration (ng/ml). (B) Myeloperoxidase–DNA levels (standard NETs). (C) Histone H3 citrullinated (absorbance 450 nm). Plasma NET levels were compared between COVID-19-related acute respiratory distress syndrome patients who will subsequently develop pulmonary embolism (PE) (n = 18) and those who will not (n = 32). (D) Total DNA concentration (ng/ml). (E) Myeloperoxidase–DNA levels (standard NETs). (F) Histone H3 citrullinated (absorbance 450 nm). **p < 0.01, ***p < 0.001, NS, statistically non-significant.